Table 2.
Monoclonal antibodies’ efficacy in different comorbidities.
| Allergic Rhinitis | Nasal polyps | Urticaria | Atopic dermatitis | Vasculitis (EGPA) | |
|---|---|---|---|---|---|
| Omalizumab | Yes | Yes | Yes | ||
| Mepolizumab | Yes | Yes | |||
| Reslizumab | |||||
| Benralizumab | |||||
| Dupilumab | Yes | Yes | |||
| Tezepelumab |
EGPA, eosinophilic granulomatosis with polyangiitis.